DCTH DELCATH SYSTEMS, INC.

Nasdaq delcath.com


$ 8.94 $ 0.32 (3.72 %)    

Friday, 14-Nov-2025 15:54:50 EST
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 8.93
$ 8.44
$ 8.93 x 101
$ 8.94 x 218
$ 8.51 - $ 9.18
$ 8.33 - $ 18.23
690,299
na
315.35M
$ 1.15
$ 263.23
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-06-2025 01-01-1970 10-K
5 11-08-2024 09-30-2024 10-Q
6 08-05-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 03-26-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-22-2023 03-31-2023 10-Q
12 03-27-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-30-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-10-2021 06-30-2021 10-Q
19 05-11-2021 03-31-2021 10-Q
20 03-31-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 05-14-2020 03-31-2020 10-Q
24 03-25-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 07-17-2019 03-31-2019 10-Q
28 06-14-2019 12-31-2018 10-K
29 11-13-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-16-2018 12-31-2017 10-K
33 11-14-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 03-29-2017 12-31-2016 10-K
37 11-10-2016 09-30-2016 10-Q
38 08-15-2016 06-30-2016 10-Q
39 05-04-2016 03-31-2016 10-Q
40 03-18-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 delcath-systems-announces-retrospective-study-from-the-university-of-tubingen-analyzing-long-term-survivors-with-liver-metastases-from-uveal-melanoma

Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on...

 stephens--co-maintains-overweight-on-delcath-systems-lowers-price-target-to-18

Stephens & Co. analyst Sudan Loganathan maintains Delcath Systems (NASDAQ:DCTH) with a Overweight and lowers the price t...

 btig-reiterates-buy-on-delcath-systems-maintains-23-price-target

BTIG analyst Marie Thibault reiterates Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $23 price target.

 delcath-systems-q3-eps-002-beats-001-estimate-sales-20563m-miss-20907m-estimate

Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.01...

 canaccord-genuity-maintains-buy-on-delcath-systems-maintains-21-price-target

Canaccord Genuity analyst John Newman maintains Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $21 price target.

 hc-wainwright--co-maintains-buy-on-delcath-systems-lowers-price-target-to-30

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and lowers the pri...

 reported-saturday-delcath-systems-posts-205m-q3-revenue-08m-net-income-and-87-gross-margin-sees-2025-revenue-outlook-of-83m85m-with-150-treatment-volume-growth-forecast

Preliminary Third Quarter Financial Results (unaudited)Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 millionHEP...

 delcath-systems-announces-the-acceptance-of-an-oral-presentation-on-results-from-the-investigator-initiated-chopin-randomized-phase-2-trial-at-the-2025-european-society-for-medical-oncology-annual-congress

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic live...

 hc-wainwright--co-maintains-buy-on-delcath-systems-raises-price-target-to-31

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the pri...

 delcath-systems-q2-eps-007-beats-002-estimate-sales-2416m-beat-2283m-estimate

Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.02...

 stephens--co-reiterates-overweight-on-delcath-systems-maintains-25-price-target

Stephens & Co. analyst Sudan Loganathan reiterates Delcath Systems (NASDAQ:DCTH) with a Overweight and maintains $25 pri...

 hc-wainwright--co-maintains-buy-on-delcath-systems-raises-price-target-to-29

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION